Study to Assess PK, Safety and Tolerability Early in Healthy Subjects

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of QHRD106 early in Chinese healthy subjects with single doses.

Timeline

Start

2021-07-05

Primary completion

2022-07-22

Completion

2023-01-06

Publications

• Huang L, Sun R, Song H, Chen Z, Hong Y, Yang H, Zhang Y, Wei L, Fei F, Li J. The first-in-human study of QHRD106 functioning as a safe and effective long-acting kallikrein drug potentially aiding ischemic stroke. Expert Opin Investig Drugs. 2024 Dec;33(12):1257-1265. doi: 10.1080/13543784.2024.2430200. Epub 2024 Nov 19.

Drugs

Indications